Jianhua Chen Selected Research

aumolertinib

1/2022	Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial.
1/2022	AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jianhua Chen Research Topics

Disease

66	Neoplasms (Cancer) 04/2024 - 09/2004
31	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2024 - 09/2013
11	Schizophrenia (Dementia Praecox) 12/2024 - 01/2012
11	Neoplasm Metastasis (Metastasis) 01/2024 - 06/2013
8	Lung Neoplasms (Lung Cancer) 01/2022 - 09/2004
7	Type 2 Diabetes Mellitus (MODY) 12/2024 - 09/2012
6	Disease Progression 02/2024 - 09/2013
6	Hypoxia (Hypoxemia) 02/2022 - 01/2013
6	Neutropenia 01/2022 - 01/2014
6	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2013
6	Gout 01/2022 - 05/2015
6	Leukopenia 01/2022 - 03/2015
5	Osteosarcoma (Osteogenic Sarcoma) 01/2020 - 10/2016
4	Seizures (Absence Seizure) 04/2023 - 01/2013
4	Melanoma (Melanoma, Malignant) 12/2022 - 01/2019
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 01/2018
4	Exanthema (Rash) 01/2022 - 09/2013
4	Hyperuricemia 01/2022 - 05/2016
4	Carcinoma (Carcinomatosis) 08/2021 - 09/2011
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 12/2024 - 01/2015
3	COVID-19 03/2024 - 01/2022
3	Major Depressive Disorder (Major Depressive Disorders) 12/2023 - 10/2015
3	Inflammation (Inflammations) 12/2023 - 11/2021
3	Infections 07/2023 - 01/2020
3	Fever (Fevers) 07/2023 - 07/2010
3	Esophageal Squamous Cell Carcinoma 10/2022 - 01/2020
3	Diarrhea 10/2022 - 01/2022
3	Adenocarcinoma of Lung 07/2022 - 01/2020
3	Uterine Cervical Neoplasms (Cancer of the Cervix) 08/2021 - 08/2013
3	Rectal Neoplasms (Rectal Cancer) 07/2021 - 01/2020
3	Glioma (Gliomas) 01/2021 - 07/2017
3	Anemia 01/2021 - 01/2014
3	Epilepsy (Aura) 01/2021 - 01/2013
3	Chronic Obstructive Pulmonary Disease (COPD) 01/2019 - 01/2017
3	Mental Disorders (Mental Disorder) 10/2015 - 01/2014
2	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2024 - 09/2011
2	Stomach Neoplasms (Stomach Cancer) 10/2023 - 01/2020
2	Substance-Related Disorders (Drug Abuse) 01/2023 - 01/2021
2	Dementia (Dementias) 01/2023 - 01/2014
2	Macular Degeneration (Age-Related Maculopathy) 12/2022 - 09/2011
2	Respiratory Insufficiency (Respiratory Failure) 01/2022 - 01/2018

Drug/Important Bio-Agent (IBA)

16	Biomarkers (Surrogate Marker)IBA 01/2024 - 01/2013
15	Proteins (Proteins, Gene)FDA Link 04/2024 - 10/2012
8	camrelizumabIBA 07/2023 - 01/2020
7	Cisplatin (Platino)FDA LinkGeneric 01/2023 - 11/2004
7	Peptides (Polypeptides)IBA 04/2014 - 09/2004
6	RNA (Ribonucleic Acid)IBA 12/2024 - 11/2020
6	Pemetrexed (MTA)FDA Link 01/2022 - 01/2014
5	Paclitaxel (Taxol)FDA LinkGeneric 01/2024 - 12/2014
5	CollagenIBA 12/2023 - 01/2019
5	Immune Checkpoint InhibitorsIBA 12/2022 - 12/2019
5	Facilitative Glucose Transport Proteins (Glucose Transporter)IBA 02/2022 - 01/2013
5	Uric Acid (Urate)IBA 01/2022 - 05/2015
5	PlatinumIBA 01/2022 - 01/2014
4	Antipsychotic Agents (Antipsychotics)IBA 12/2024 - 01/2015
4	CrizotinibIBA 02/2024 - 01/2020
4	Docetaxel (Taxotere)FDA Link 10/2022 - 01/2014
4	Adenosine Triphosphate (ATP)IBA 02/2022 - 01/2019
4	Clozapine (Clozaril)FDA LinkGeneric 06/2021 - 01/2015
4	MicroRNAs (MicroRNA)IBA 01/2020 - 01/2019
4	Cadherins (E-Cadherin)IBA 01/2020 - 03/2014
4	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2007 - 02/2005
3	Reactive Oxygen Species (Oxygen Radicals)IBA 05/2024 - 03/2023
3	ensartinibIBA 02/2024 - 01/2020
3	Carboplatin (JM8)FDA LinkGeneric 01/2024 - 01/2018
3	Messenger RNA (mRNA)IBA 12/2023 - 01/2016
3	Therapeutic UsesIBA 12/2022 - 10/2020
3	LigandsIBA 12/2022 - 04/2020
3	Programmed Cell Death 1 ReceptorIBA 10/2022 - 01/2022
3	AcidsIBA 07/2022 - 09/2005
3	Nucleic AcidsIBA 01/2022 - 11/2016
3	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 09/2011
3	Circulating Tumor DNAIBA 01/2021 - 11/2019
3	Cysteine (L-Cysteine)FDA Link 01/2021 - 05/2019
3	ErbB Receptors (EGF Receptor)IBA 01/2021 - 11/2019
3	Small Interfering RNA (siRNA)IBA 01/2020 - 07/2017
3	MutagensIBA 04/2014 - 11/2004
3	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 01/2007 - 02/2005
3	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2007 - 09/2005
2	Carrier Proteins (Binding Protein)IBA 04/2024 - 10/2012
2	Anaplastic Lymphoma KinaseIBA 02/2024 - 01/2024
2	Tyrosine Kinase InhibitorsIBA 01/2024 - 01/2020
2	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 12/2023 - 01/2020
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2023 - 01/2013
2	sugemalimabIBA 01/2023 - 01/2022
2	AntibodiesIBA 12/2022 - 09/2009
2	Gefitinib (Iressa)FDA Link 01/2022 - 09/2013
2	MetalsIBA 01/2022 - 01/2018
2	Monoclonal AntibodiesIBA 01/2022 - 01/2021
2	Immunoglobulins (Immunoglobulin)IBA 01/2022 - 01/2021

Therapy/Procedure

30	Therapeutics 01/2024 - 11/2004
22	Drug Therapy (Chemotherapy) 01/2024 - 01/2014
6	Immunotherapy 08/2023 - 12/2019
6	Radiotherapy 11/2017 - 09/2004
3	Chemoradiotherapy 01/2024 - 01/2020
3	Radiofrequency Ablation 01/2022 - 01/2021
2	Moxibustion 01/2023 - 01/2022
2	Lasers (Laser) 09/2022 - 02/2022
2	Catheter Ablation 01/2022 - 08/2021
2	Aftercare (After-Treatment) 01/2022 - 01/2021